Clinical data revealed that RRM2 is increased in GBM tissues and inversely correlated with glioma sufferers OS time, which suggests RRM2 as a potential therapeutic target, as well as a prognosis and predictive biomarker. This evidence concerns the gene RRM2 and central nervous system cancer.